{"created":"2023-05-15T09:17:44.465680+00:00","id":741,"links":{},"metadata":{"_buckets":{"deposit":"e916ed66-8626-4907-9277-07f2214eb606"},"_deposit":{"created_by":15,"id":"741","owners":[15],"pid":{"revision_id":0,"type":"depid","value":"741"},"status":"published"},"_oai":{"id":"oai:iuhw.repo.nii.ac.jp:00000741","sets":["2:128"]},"author_link":["164","1676"],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2016-03-31","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"109","bibliographicPageStart":"101","bibliographicVolumeNumber":"21","bibliographic_titles":[{"bibliographic_title":"国際医療福祉大学学会誌"},{"bibliographic_title":"Journal of the International University of Health and Welfare","bibliographic_titleLang":"en"}]}]},"item_10001_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"We assessed how a health economic viewpoint was reflected in the recommendations of antihypertensive medications in the main clinical practice guidelines of Japan, the United States and Europe as well as in the decision processes involved. For this purpose, the European Society of Hypertension and the European Society of Cardiology (ESH/ESC) 2013 guidelines stated that all types of antihypertensive drugs could be used as first-line therapy without ranking in order of performance as treatment strategies or recommended the use of drugs, which was dependent on the clinical and social background of the individual patients. The guidelines by the Japanese Society of Hypertension (JSH) 2014, the guidelines by the Report of the Eighth Joint National Committee (JNC8) and the joint guideline by the National Institute for Health and Care Excellence and the British Hypertension Society (NICE/BHS) 2011 recommended four types of antihypertensive drugs. There was minimal information regarding the health economic viewpoint in ESH/ESC2013 and JNC8, and the recommendation of antihypertensive drugs was based on clinical evidence. JSH2014 was used in several studies concerning pharmacoeconomics but was not reflected in the resulting drug recommendations. For NICE/BSH2011, a cost-effectiveness analysis as an evaluation indicator was conducted; specific and clear treatment policies based on the results were presented in this guideline. We suggest that there is a need to create a clinical practice guideline in Japan that reflects the results of a health economic evaluation to establish the standardization and efficacy of hypertension treatment.","subitem_description_type":"Abstract"}]},"item_10001_description_6":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"日米欧の主要な診療ガイドラインにおける推奨降圧薬とその決定過程において,医療経済的視点がどの程度反映されているかを検討した.その結果,欧州高血圧学会/ 欧州心臓病学会(ESH/ESC)2013 はすべての降圧薬が対象にされており,患者の臨床的・社会的背景に応じて個別に薬物治療を行うよう記載されていた.日本高血圧学会(JSH)2014,米国合同委員会(JNC8),英国保健医療研究所/ 英国高血圧学会(NICE/BHS)2011 は4 種類が推奨されていた.推奨降圧薬の決定根拠として,JNC8,ESH/ESC2013 は医療経済学的視点による記述はほとんどなく,臨床的エビデンスを基に推奨降圧薬の決定をしていた.JSH2014 は医療経済評価を行った文献は紹介されていたが,推奨薬の決定根拠には反映されていなかった.NICE/BHS2011 では評価指標として費用効果分析を実施し,その結果から具体的で明確な薬物治療の方針を提示していた.高血圧治療の標準化と効率化を図るために,わが国においても医療経済評価の結果を反映した診療ガイドラインの必要性があると考えられた.","subitem_description_type":"Other"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"国際医療福祉大学学会"}]},"item_10001_radio_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_radio_item":"publisher"}]},"item_10001_relation_12":{"attribute_name":"NII論文ID（NAID）","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"110010022426"}]}]},"item_10001_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"CiNii"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"http://ci.nii.ac.jp/naid/110010022426","subitem_relation_type_select":"URI"}}]},"item_10001_source_id_11":{"attribute_name":"書誌レコードID（NCID）","attribute_value_mlt":[{"subitem_source_identifier":"AA12537130","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"21863652","subitem_source_identifier_type":"ISSN"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"伊藤, かおる"},{"creatorName":"イトウ, カオル","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"池田, 俊也"},{"creatorName":"イケダ, シュンヤ","creatorNameLang":"ja-Kana"}],"nameIdentifiers":[{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2016-04-26"}],"displaytype":"simple","filename":"21_1(101-109p).pdf","filesize":[{"value":"508.0 kB"}],"format":"application/pdf","licensetype":"license_11","mimetype":"application/pdf","url":{"label":"本文(PDF)","url":"https://iuhw.repo.nii.ac.jp/record/741/files/21_1(101-109p).pdf"},"version_id":"cb5b8b76-4198-49c6-9193-0d1e4a8085b7"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"高血圧","subitem_subject_scheme":"Other"},{"subitem_subject":"診療ガイドライン","subitem_subject_scheme":"Other"},{"subitem_subject":"医療経済評価","subitem_subject_scheme":"Other"},{"subitem_subject":"降圧薬","subitem_subject_scheme":"Other"},{"subitem_subject":"hypertension","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"clinical practice guideline","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"health economic evaluation","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"antihypertensive drugs","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"日米欧の高血圧診療ガイドラインにおける医療経済評価の活用状況について","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"日米欧の高血圧診療ガイドラインにおける医療経済評価の活用状況について"},{"subitem_title":"Utilization of health economic evaluations in Japan, the US and Europe in clinical practice guidelines on hypertension","subitem_title_language":"en"}]},"item_type_id":"10001","owner":"15","path":["128"],"pubdate":{"attribute_name":"公開日","attribute_value":"2016-04-26"},"publish_date":"2016-04-26","publish_status":"0","recid":"741","relation_version_is_last":true,"title":["日米欧の高血圧診療ガイドラインにおける医療経済評価の活用状況について"],"weko_creator_id":"15","weko_shared_id":-1},"updated":"2023-06-21T10:43:03.275899+00:00"}